COVID-19: NAFDAC approves production of Chloroquine for clinical trails

As the World battles for a cure of Coronavirus code-named COVID-19, the National Agency for Food and Drug Administration and Control, NAFDAC, has approved the production of Chloroquine for clinical trials.

Chloroquine is a medication which is majorly used to prevent and to treat malaria in areas where malaria is known to be sensitive to its effects.

While making the announcement Friday, at the NAFDAC headquarters in Lagos, the Director-General of the agency, Mojisola Adeyeye, pointed out that NAFDAC is not approving Chloroquine for the treatment of  COVID-19 but for clinical trials to find treatment for the virus.

READ ALSO: Breaking: Donald Trump approves chloroquine for Coronavirus treatment

“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.

She, therefore, called on experts

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.